Shaalan Beg, Senior Advisor for Clinical Research at the National Cancer Institute (NCI), shared a post on X by Emil Lou, Professor with tenure at the University of Minnesota, adding:

“Exciting early data for new treatment of cancers that are refractory to currently available checkpoint inhibitors.
Targeting immune checkpoint CISH w CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer Emil Lou.”

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial

Authors: Emil Lou et al.

Chadi Nabhan

Quoting Emil Lou‘s post:

“It’s not only uncovering what is causing young-adult cases, but also how we can devise better ways to treat it.

At today’s AACR25 session on Innovative Approaches to Key Molecular Targets, I will present work targeting a novel intracellular immune checkpoint using cell therapy.”

Chadi Nabhan

Learn more about Shaalan Beg and colorectal cancer on OncoDaily.

Shaalan Beg highlights Emil Lou’s presentation on CRISPR-Cas9-edited T cells targeting CISH in metastatic colorectal cancer at AACR25

“Exciting early data for new treatment of cancers that are refractory to currently available checkpoint inhibitors.
Targeting immune checkpoint CISH w CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer Emil Lou.”

“It’s not only uncovering what is causing young-adult cases, but also how we can devise better ways to treat it.

At today’s AACR25 session on Innovative Approaches to Key Molecular Targets, I will present work targeting a novel intracellular immune checkpoint using cell therapy.”

Shaalan Beg highlights Emil Lou’s presentation on CRISPR-Cas9-edited T cells targeting CISH in metastatic colorectal cancer at AACR25

“Exciting early data for new treatment of cancers that are refractory to currently available checkpoint inhibitors. Targeting immune checkpoint CISH w CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer Emil Lou.”

“It’s not only uncovering what is causing young-adult cases, but also how we can devise better ways to treat it.

At today’s AACR25 session on Innovative Approaches to Key Molecular Targets, I will present work targeting a novel intracellular immune checkpoint using cell therapy.”

“Exciting early data for new treatment of cancers that are refractory to currently available checkpoint inhibitors.
Targeting immune checkpoint CISH w CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer Emil Lou.”